Presented By John Byrd at 2014 ASCO Annual Meeting

1. Randomized Comparison of Ibrutinib Versus Ofatumumab in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the Phase III <br />RESONATETM Trial Presented By John Byrd at 2014 ASCO Annual Meeting

2. Background Presented By John Byrd at 2014 ASCO Annual Meeting

3. RESONATE™ Phase 3 Study Design Presented By John Byrd at 2014 ASCO Annual Meeting

4. Study Objectives Presented By John Byrd at 2014 ASCO Annual Meeting

5. Inclusion Criteria Presented By John Byrd at 2014 ASCO Annual Meeting

6. Patient Disposition Presented By John Byrd at 2014 ASCO Annual Meeting

7. Baseline Characteristics Presented By John Byrd at 2014 ASCO Annual Meeting

8. Progression-Free Survival Presented By John Byrd at 2014 ASCO Annual Meeting

9. Progression-Free Survival by Baseline Characteristics and Molecular Features Presented By John Byrd at 2014 ASCO Annual Meeting

10. Overall Survival Presented By John Byrd at 2014 ASCO Annual Meeting

11. Overall Response to Therapy: <br />IRC and Investigator Assessment Presented By John Byrd at 2014 ASCO Annual Meeting

12. Best IRC Response without Second CT Confirmation Presented By John Byrd at 2014 ASCO Annual Meeting

13. Safety: Adverse Events (≥15%) Regardless of Attributiona Presented By John Byrd at 2014 ASCO Annual Meeting

14. Safety Overview Presented By John Byrd at 2014 ASCO Annual Meeting

15. Safety: Atrial Fibrillation and Bleeding-Related Adverse Events Presented By John Byrd at 2014 ASCO Annual Meeting

16. Conclusions Presented By John Byrd at 2014 ASCO Annual Meeting

17. Acknowledgments Presented By John Byrd at 2014 ASCO Annual Meeting

18. Acknowledgments Presented By John Byrd at 2014 ASCO Annual Meeting